Lu Ziyi, Zhang Kexin, Huang Junyue, Zhang Shoukai
The First Clinical Medicine College, Gansu University of Chinese Medicine, Lanzhou, Gansu, 730000, China.
Department of Nephrology, Gansu Provincial Hospital, Lanzhou, Gansu, 730000, China.
BMC Nephrol. 2025 May 20;26(1):250. doi: 10.1186/s12882-025-04177-1.
Secondary hyperparathyroidism (SHPT) is a common complication of Chronic kidney disease (CKD), which is mainly manifested by the overproduction of Parathyroid hormone (PTH), leading to multi-system pathologies such as calcium and phosphorus metabolism disorders, skeletal lesions, and cardiovascular diseases, which seriously affects the quality of life of patients. In recent years, the role of microRNAs (miRNAs) in the pathogenesis of SHPT has been gradually revealed, providing new research directions for diagnosing and treating the disease. miRNAs play an important role in the development of SHPT by regulating genes related to calcium-phosphorus metabolism, influencing the stability and translational efficiency of PTH mRNAs, and regulating the proliferation and apoptosis of parathyroid cells. miRNA-based gene therapy strategies (e.g., miRNA antagonists or mimics) have shown promising therapeutic effects in animal models, but their clinical translation still faces challenges such as targeted delivery and safety. This review aims to summarize the mechanistic roles of miRNA and the progress of research in SHPT studies to provide a theoretical basis for diagnosing and treating SHPT.
继发性甲状旁腺功能亢进（SHPT）是慢性肾脏病（CKD）的常见并发症，主要表现为甲状旁腺激素（PTH）过度分泌，导致钙磷代谢紊乱、骨骼病变和心血管疾病等多系统病变，严重影响患者生活质量。近年来，微小RNA（miRNA）在SHPT发病机制中的作用逐渐被揭示，为该疾病的诊断和治疗提供了新的研究方向。miRNA通过调节钙磷代谢相关基因、影响PTH mRNA的稳定性和翻译效率以及调节甲状旁腺细胞的增殖和凋亡，在SHPT的发生发展中发挥重要作用。基于miRNA的基因治疗策略（如miRNA拮抗剂或模拟物）在动物模型中已显示出有前景的治疗效果，但其临床转化仍面临靶向递送和安全性等挑战。本综述旨在总结miRNA的作用机制以及SHPT研究的进展，为SHPT的诊断和治疗提供理论依据。
